Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Mar 4;12(1):22.
doi: 10.1186/s13045-019-0706-9.

Mortality of lymphoma and myeloma in China, 2004-2017: an observational study

Weiping Liu  1 , Jiangmei Liu  2 , Yuqin Song  1 , Xiaopei Wang  1 , Maigeng Zhou  2 , Lijun Wang  3 , Jun Ma  4 , Jun Zhu  5 ; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology, Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology
Affiliations
Observational Study

Mortality of lymphoma and myeloma in China, 2004-2017: an observational study

Weiping Liu et al. J Hematol Oncol. .

Abstract

Background: There is a dearth of accurate information about patterns of mortality of lymphoid neoplasms and temporal trends in China. In this nationwide mortality study, we aimed to assess the mortality of lymphoma and myeloma in 2017 and the changes in the trend from 2004 to 2016.

Methods: Death certificate data obtained from the Chinese Center for Disease Control and Prevention's disease surveillance points system (CDC-DSP) and population data from the National Bureau of Statistics of China were used in this study. We described the mortality of lymphoma and myeloma in 2017 by age group, sex, residence, and region and evaluated the temporal trend from 2004 to 2016 using joinpoint regression.

Results: An estimated 52,000 deaths associated with lymphoma and myeloma occurred in 2017. The age-standardized mortality rate China (ASMRC) and age-standardized mortality rate worldwide (ASMRW) per 100,000 were 3.74 and 2.60, respectively. Males had higher ASMRC than females (4.54 vs. 2.91 per 100,000). The ASMRC in urban areas was significantly higher than that in rural areas (4.35 vs. 3.47 per 100,000). The age-specific mortality rate showed an upward trend with age and reached a maximum in the age group of over 85 years. In terms of regional variation, Eastern China had the highest mortality rate (3.43/100,000), followed by Central China (3.10/100,000) and Western China (3.02/100,000). The mortality rates of lymphoma and myeloma increased annually by 4.5% during the period 2004-2016, with a significant rapid upward trend in rural areas since 2007.

Conclusions: The mortality of lymphoma and myeloma increased in China from 2004 to 2017. The rapid increase in disease burden in rural areas highlights new challenges for disease prevention and control strategies.

Keywords: Epidemiology; Lymphoma; Mortality; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Age-specific mortality of lymphoma and myeloma by sex in China, 2017
Fig. 2
Fig. 2
Trends in mortality of lymphoma and myeloma (age-standardized to the Chinese standard population) by sex: China, 2004 to 2017
Fig. 3
Fig. 3
Trends in mortality of lymphoma and myeloma (age-standardized to the Chinese standard population) by residence: China, 2004 to 2017
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568. doi: 10.1001/jamaoncol.2018.2706. - DOI - PMC - PubMed
    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459. doi: 10.3322/caac.21357. - DOI - PubMed
    1. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014. JAMA. 2017;317(4):388–406. doi: 10.1001/jama.2016.20324. - DOI - PMC - PubMed
    1. Lee H, Park HJ, Park EH, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 2018;50:222–238. doi: 10.4143/crt.2017.093. - DOI - PMC - PubMed

Publication types